Anika Therapeutics, Inc. (ANIK)
21.57
+0.46
(+2.18%)
USD |
NASDAQ |
Sep 02, 16:00
21.57
0.00 (0.00%)
After-Hours: 17:49
Anika Therapeutics Research and Development Expense (TTM) : 27.45M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.45M |
| March 31, 2026 | 26.42M |
| December 31, 2025 | 25.77M |
| September 30, 2025 | 25.82M |
| June 30, 2025 | 24.82M |
| March 31, 2025 | 25.19M |
| December 31, 2024 | 25.54M |
| September 30, 2024 | 24.57M |
| June 30, 2024 | 26.42M |
| March 31, 2024 | 28.65M |
| December 31, 2023 | 30.64M |
| September 30, 2023 | 32.85M |
| June 30, 2023 | 32.36M |
| March 31, 2023 | 30.42M |
| December 31, 2022 | 28.18M |
| September 30, 2022 | 26.43M |
| June 30, 2022 | 26.80M |
| March 31, 2022 | 27.12M |
| December 31, 2021 | 27.33M |
| September 30, 2021 | 27.54M |
| June 30, 2021 | 25.09M |
| March 31, 2021 | 22.33M |
| December 31, 2020 | 22.02M |
| September 30, 2020 | 19.88M |
| June 30, 2020 | 18.82M |
| Date | Value |
|---|---|
| March 31, 2020 | 18.46M |
| December 31, 2019 | 16.66M |
| September 30, 2019 | 16.64M |
| June 30, 2019 | 16.72M |
| March 31, 2019 | 17.29M |
| December 31, 2018 | 18.19M |
| September 30, 2018 | 18.39M |
| June 30, 2018 | 20.00M |
| March 31, 2018 | 19.72M |
| December 31, 2017 | 18.79M |
| September 30, 2017 | 17.48M |
| June 30, 2017 | 14.46M |
| March 31, 2017 | 12.80M |
| December 31, 2016 | 10.73M |
| September 30, 2016 | 10.79M |
| June 30, 2016 | 10.03M |
| March 31, 2016 | 9.049M |
| December 31, 2015 | 8.988M |
| September 30, 2015 | 7.955M |
| June 30, 2015 | 7.893M |
| March 31, 2015 | 7.954M |
| December 31, 2014 | 8.144M |
| September 30, 2014 | 8.191M |
| June 30, 2014 | 7.809M |
| March 31, 2014 | 7.765M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Perspective Therapeutics, Inc. | 82.13M |
| MiMedx Group, Inc. | 15.38M |
| ABVC BioPharma, Inc. | 0.1148M |
| Enovis Corp. | 124.32M |
| Edwards Lifesciences Corp. | 1.091B |